JPMorgan BetaBuilders U.S. Mid Cap Equity ETF · CBOE:BBMC
JPMorgan BetaBuilders U.S. Mid Cap Equity ETF — Q1 2025 Earnings Presentation
9 slides from JPMorgan BetaBuilders U.S. Mid Cap Equity ETF's earnings presentation, May 2025
Slide 1: Medtech Q1 2025: Strategic shifts and market dynamics
Medtech Q1 2025: Strategic shifts and market dynamics May 2025 Fueled by
Slide 2: Executive Summary
Executive Summary Medtech venture investments and licensing activity showed meaningful deal count—with key concentrations Medtech venture investment activity continued to see larger J.P. Morgan is committed to your success. Our relationships, our Parameters rounds into fewer companies to post a high
Slide 3: Medtech venture activity: Bigger bets, fewer players
Medtech venture activity: Bigger bets, fewer players Strong medtech venture dollar momentum continues Total Venture Investments in Medtech ($B) Total Deal Value ($B) Federal Funds Effective Rate Total Amount Raised ($B) Number of Rounds 6.00 $30.0 672 $24.5 5.00 Q1 2025 medtech venture dollars toppe
Slide 4: Mega rounds drive medtech momentum
Mega rounds drive medtech momentum Large venture rounds and large licensing payments came from fewer transactions overall in Q1 2025 Medtech: Total Number of Venture Rounds and R&D Partnership & License Deals by Value Upfront Number of Venture Investments by Round Size Number of R&D Licenses by Disc
Slide 5: Early-stage medtech: While dollars invested shows growth, headwinds remain
Early-stage medtech: While dollars invested shows growth, headwinds remain Seed and Series A vs. Later Series Venture Totals in Medtech Q1 2025 first-time financing had fewer deals relative Total of Seed and Series A Rounds ($B) Total of Series B and Later Rounds ($B) to a year ago, with one large o
Slide 6: Licensing deals: Activity remains robust with examples of large upfront payments
Licensing deals: Activity remains robust with examples of large upfront payments Medtech: R&D Partnership, Licensing and Contracting Totals ($B) and Percentage Upfront Medtech licensing and R&D partnership deal activity started strong in 2025 as deal count nearly doubled from Q1 2024 to Total Deal V
Slide 7: M&A: Fewer deals, bigger dollars
M&A: Fewer deals, bigger dollars Quarterly medtech M&A activity tempered with Medtech M&A: Number of Deals, Total Deal Value ($B) and Median M&A Upfront Cash and Equity ($M) fewer but larger deals Total M&A Cash No Contingents ($B) Number of Deals $30.0 $22.9 53 62 $21.5 54 57 40 $18.8 47 $20.0 34 3
Slide 8: IPO spotlight: Medtech able to point to 2 distinct IPOs
IPO spotlight: Medtech able to point to 2 distinct IPOs Medtech IPOs still show tentative signs of market Nasdaq and NYSE Completed IPOs in Medtech: Totals ($B) and Count appetite, but far below 2020 and 2021 levels Total Amount Raised ($B) Number of IPOs $8.0 36 $6.8 $7.0 Medtech IPO activity retur
Slide 9: Chase, J.P. Morgan, JPMorgan, and JPMorgan Chase are marketing names
Chase, J.P. Morgan, JPMorgan, and JPMorgan Chase are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldw ide (collectively, “JPMC”, “We”, “Our” or “Us”, as the context may require). We prepared these materials for discussion purposes only and for
JPMorgan BetaBuilders U.S. Mid Cap Equity ETF — Q1 2025 Earnings Presentation on 6ix